Targeted molecular cancer therapies offer new options for cancer patients. As targeted cancer therapies supplant conventional chemotherapies in clinical oncology practices, many cancer patients who do not meet a specific genomic profile are unable to benefit from the new therapies. In fact a majority of cancer patients cannot benefit from targeted therapies. Genprex technologies bridge a critical gap by combining with targeted therapies to provide treatments to large patient populations who would otherwise not be candidates for targeted therapies. For example, Oncoprex® therapy is being combined with the EGFR TKI drug Tarceva® (erlotinib) in Stage IIIb/IV NSCLC patients without an activating EGFR mutation (prior chemo) and patients with an activating EGFR mutation, progressing on erlotinib. Patients without the EGFR mutation represent the vast majority of cancer patients, however these patients are usually not candidates for EGFR TKI therapies because of their genomic status. Genprex technologies are being developed to overcome genomic limitations, inherent in targeted therapies, to provide new treatment solutions to large cancer patient populations.